D. Western Therapeutics Institute (TSE:4576) Cyclically Adjusted PS Ratio: (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4576 D. Western Therapeutics Institute Inc TSE:4576
46 GF Score
Price 円78.00
GF Value 円68.30
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is D. Western Therapeutics Institute Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


D. Western Therapeutics Institute  (TSE:4576) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


D. Western Therapeutics Institute Cyclically Adjusted PS Ratio Related Terms


D. Western Therapeutics Institute Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

D. Western Therapeutics Institute Cyclically Adjusted PS Ratio Chart

D. Western Therapeutics Institute Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.24 21.93 11.20 0.00 0.00

D. Western Therapeutics Institute Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.05 9.75 0.00 0.00 0.00

TSE:4576 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


D. Western Therapeutics Institute Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where D. Western Therapeutics Institute's Cyclically Adjusted PS Ratio falls into.


TSE:4576
46GF Score
D. Western Therapeutics Institute Inc TSE:4576
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

D. Western Therapeutics Institute Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

D. Western Therapeutics Institute's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 is calculated as:

For example, D. Western Therapeutics Institute's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0/113.0000*113.0000
=0.000

Current CPI (Dec. 2025) = 113.0000.

D. Western Therapeutics Institute Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 0.917 98.100 1.056
201603 3.058 97.900 3.530
201606 1.045 98.100 1.204
201609 1.036 98.000 1.195
201612 1.869 98.400 2.146
201703 1.130 98.100 1.302
201706 1.909 98.500 2.190
201709 4.323 98.800 4.944
201712 2.337 99.400 2.657
201803 2.047 99.200 2.332
201806 2.479 99.200 2.824
201809 3.313 99.900 3.747
201812 3.311 99.700 3.753
201903 10.491 99.700 11.891
201906 3.333 99.800 3.774
201909 3.372 100.100 3.807
201912 4.899 100.500 5.508
202003 2.839 100.300 3.198
202006 2.922 99.900 3.305
202009 3.045 99.900 3.444
202012 3.931 99.300 4.473
202103 3.063 99.900 3.465
202106 3.812 99.500 4.329
202109 3.893 100.100 4.395
202112 3.356 100.100 3.788
202203 3.737 101.100 4.177
202206 3.408 101.800 3.783
202209 3.340 103.100 3.661
202212 4.501 104.100 4.886
202303 2.886 104.400 3.124
202306 3.058 105.200 3.285
202309 3.931 106.200 4.183
202312 3.559 106.800 3.766
202403 3.263 107.200 3.440
202406 3.578 108.200 3.737
202412 0.000 110.700 0.000
202503 2.199 111.100 2.237
202506 1.709 111.700 1.729
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?

Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued. The current stock price of 円78.00 is trading 14.2% above its estimated GF Value™ of 円68.30. GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.

Key valuation signals for TSE:4576:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: 円68.30 vs. price of 円78.00 (14.2% above fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


D. Western Therapeutics Institute Business Description

Other Exchanges 6DW:Germany
Address 7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
46GF Score

Get the complete analysis for TSE:4576

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円78.00
Price
円68.30
GF Value